Vanguard Group’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.91M | Sell |
442,626
-44,260
| -9% | -$391K | ﹤0.01% | 3297 |
|
|
2025
Q1 | $5.24M | Sell |
486,886
-1,418
| -0.3% | -$15.3K | ﹤0.01% | 3153 |
|
|
2024
Q4 | $6.25M | Sell |
488,304
-15,270
| -3% | -$195K | ﹤0.01% | 3175 |
|
|
2024
Q3 | $13.9M | Sell |
503,574
-166,341
| -25% | -$4.59M | ﹤0.01% | 2791 |
|
|
2024
Q2 | $19.4M | Buy |
669,915
+494
| +0.1% | +$14.3K | ﹤0.01% | 2584 |
|
|
2024
Q1 | $29.9M | Sell |
669,421
-10,780
| -2% | -$481K | ﹤0.01% | 2401 |
|
|
2023
Q4 | $26.4M | Sell |
680,201
-165,285
| -20% | -$6.41M | ﹤0.01% | 2472 |
|
|
2023
Q3 | $24.9M | Buy |
845,486
+1,623
| +0.2% | +$47.7K | ﹤0.01% | 2463 |
|
|
2023
Q2 | $53.7M | Buy |
843,863
+205,907
| +32% | +$13.1M | ﹤0.01% | 2151 |
|
|
2023
Q1 | $30.1M | Buy |
637,956
+8,394
| +1% | +$396K | ﹤0.01% | 2411 |
|
|
2022
Q4 | $43.7M | Buy |
629,562
+9,231
| +1% | +$641K | ﹤0.01% | 2248 |
|
|
2022
Q3 | $90.9M | Buy |
620,331
+88,831
| +17% | +$13M | ﹤0.01% | 1844 |
|
|
2022
Q2 | $69.3M | Buy |
531,500
+92,565
| +21% | +$12.1M | ﹤0.01% | 2027 |
|
|
2022
Q1 | $44.3M | Buy |
438,935
+331,781
| +310% | +$33.5M | ﹤0.01% | 2373 |
|
|
2021
Q4 | $16.6M | Sell |
107,154
-3,487
| -3% | -$540K | ﹤0.01% | 2938 |
|
|
2021
Q3 | $32.7M | Buy |
110,641
+23,172
| +26% | +$6.86M | ﹤0.01% | 2597 |
|
|
2021
Q2 | $28.4M | Buy |
+87,469
| New | +$28.4M | ﹤0.01% | 2657 |
|